neutral
9 days agoCorona Remedies sets launch window for mainboard IPO amid pharma expansion
Corona Remedies will open its mainboard IPO from December 8 to 10, targeting ₹500 crore through a fresh issue priced at ₹1008–1062 per share. The company plans to fund capacity expansion and product development initiatives. Allotment is scheduled for December 11, with listing on December 15. Grey market signals indicated a premium of around 15%, reflecting early investor interest in the healthcare segment.
Companies:
- Corona Remedies
Tags:
- ipo
- pharma
Explore:Mutual Fund Home
neutral
9 days agoCorona Remedies sets launch window for mainboard IPO amid pharma expansion
Corona Remedies will open its mainboard IPO from December 8 to 10, targeting ₹500 crore through a fresh issue priced at ₹1008–1062 per share. The company plans to fund capacity expansion and product development initiatives. Allotment is scheduled for December 11, with listing on December 15. Grey market signals indicated a premium of around 15%, reflecting early investor interest in the healthcare segment.
Companies:
- Corona Remedies
Tags:
- ipo
- pharma
Explore:Mutual Fund Home
1 min read
63 words
Corona Remedies’ ₹500 crore IPO opens December 8–10 with a ₹1008–1062 price band, aiming to fund pharma expansion ahead of its December 15 listing.
Corona Remedies will open its mainboard IPO from December 8 to 10, targeting ₹500 crore through a fresh issue priced at ₹1008–1062 per share. The company plans to fund capacity expansion and product development initiatives. Allotment is scheduled for December 11, with listing on December 15. Grey market signals indicated a premium of around 15%, reflecting early investor interest in the healthcare segment.
Corona Remedies will open its mainboard IPO from December 8 to 10, targeting ₹500 crore through a fresh issue priced at ₹1008–1062 per share. The company plans to fund capacity expansion and product development initiatives. Allotment is scheduled for December 11, with listing on December 15. Grey market signals indicated a premium of around 15%, reflecting early investor interest in the healthcare segment.
Companies:
- Corona Remedies
Tags:
- ipo
- pharma
- ipo
- pharma
- india
- markets
Dec 6, 2025 • 17:30